Michael Glen Kauffman
Independent DirectorDr. Michael Glen Kauffman, M.D., Ph.D., is President of Development & Director of Verastem, Inc. from December 15, 2025. Dr. Kauffman was Lead Independent Director of Verastem, Inc. from June 2016 to December 15, 2025. He is Independent Director of Kyntra Bio, Inc. (formerly known as FibroGen, Inc.) from June 4, 2025. He served as the President, Chief Executive Officer and Director at Nereid Therapeutics Inc. since November 2023. He is also the Executive Chairman of FoRx Therapeutics AG from 2024 and a Member of the Scientific Advisory Board at Wayfinder Biosciences Inc. since 2025. Dr. Kauffman has been a Director BiVictriX Therapeutics plc (formerly known as BiVictriX plc) since May 23, 2025 and served as its Non-Executive Director from January 2022 and had been its Non-Executive Chairman since January 6, 2023 until May 23, 2025. Additionally, he is an Independent Non-Executive Director at Mirror Biologics Inc. since August 2022 and serves as a Non-Executive Director of BiVictriX Limited since January 2022. He has many years of experience in the life sciences industry, particularly in oncology therapeutic products, including expertise in preclinical research, clinical development, regulatory strategy and global approvals. He is the Independent Chairman of the Board of Parthenon Therapeutics Inc. from September 2023 and serves as an Advisor at Prime Movers Lab. Dr. Kauffman co-founded Karyopharm Therapeutics Inc. in 2008 and was its Chief Executive Officer from January 5, 2011, until May 3, 2021. He has served as the Senior Clinical Advisor at Karyopharm Therapeutics Inc. since May 3, 2021 and was the President from January 2011 to December 2013 and Chief Medical Officer from December 2012 until December 2013. He also serves as a Director of Metamark Genetics, Inc. and was the Interim Executive Director of Metamark Genetics, Inc. until April 2013. Dr. Kauffman had been an Independent Director of Kezar Life Sciences, Inc. since December 2016 until May 11, 2026 and served as a Director of Infinity Pharmaceuticals, Inc. from August 2020 until 2020. Previously, he held various senior positions, including Chief Medical Officer at Onyx Pharmaceuticals, Inc. from November 2009 to December 31, 2010 and Interim Chief Medical Officer from November 2009 to February 1, 2010. He was the Chief Medical Officer of Proteolix Pharmaceuticals from November 2008 to November 2009, where he oversaw the clinical development of carfilzomib, leading to its approval by the FDA in July 2012. Dr. Kauffman also served as President at EPIX Pharmaceuticals, Inc. from 2006 to 2008 and Chief Executive Officer from August 16, 2006, to July 25, 2008. He has held senior positions at Biogen Idec, Inc., where he served as Medical Director of the Inflammation Program and at Millennium Pharmaceuticals, Inc., where he was Vice President of Medicine and led the VELCADE Development Program. Dr. Kauffman has authored numerous medical publications and is board certified in internal medicine. He received his M.D. and Ph.D. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University in 1992 and performed his postdoctoral training at Harvard University. He holds a B.A. Degree in Biochemistry, summa cum laude, from Amherst College. He is trained in Internal Medicine at Beth Israel (Deaconess) Medical Center and in Rheumatology at Massachusetts General Hospital and is board certified in Internal Medicine.
Positions
- Company NameKyntra Bio, Inc.Stock CodeKYNBPositionIndependent DirectorColleagues
- TWThane WettigCEO & Director
- JAJames A. SchoeneckIndependent Chairman of the Board
- DDDavid DeLuciaSenior VP & CFO
- JAJohn AldenCorporate Secretary & General Counsel
- MSMichelle SimonettiHead of People and Culture & Executive Director
- CBCarrie BrownsteinChief Medical Officer
- JLJeffrey L. EdwardsIndependent Director
- AEAndrew E. SingerIndependent Director
- Company NameVerastem, Inc.Stock CodeVSTMPositionPresident of Development & DirectorColleagues
- DWDaniel W. PatersonPresident, CEO & Director
- JHJohn H. JohnsonIndependent Chairman
- DCDaniel CalkinsChief Financial Officer
- MGMichael Glen KauffmanPresident of Development & Director
- RARobert A. WeinbergCo-Founder & Chair of Scientific Advisory Board
- MDMichelle DetwilerCo-Founder
- MJMichelle J. RobertsonIndependent Director
